45 Search Results for Lymphoma
While the availability of novel therapies is making the future brighter for non-Hodgkin’s lymphoma (NHL) patients, new treatments also are coming on line for Hodgkin’s lymphoma, which is a hematological cancer distinct from NHL.
Because several studies have suggested it fails to increase overall survival (OS) despite prolonging progression-free survival (PFS), use of maintenance rituximab (MR) following chemoimmunotherapy in follicular lymphoma (FL) remains controversial.
Bleomycin, the first line standard of care for Hodgkin lymphoma causes pulmonary events in some patients, but physicians have been uncertain how many patients are affected and how long they remain at risk.
Long-term survival in patients with aggressive peripheral T-cell lymphoma (PTCL) is generally poor, no clear consensus exists on optimal initial therapy, according to a new study.
After decades on the sidelines, research in cutaneous T-cell lymphoma (CTCL) has exploded in recent years, bringing patients with this rare disease new opportunities for treatment.
PORTLAND, OR—High response rates can be achieved with first-line high-dose methotrexate (HD-MTX) based regimens for primary central nervous system lymphoma (PCNSL), but many patients relapse within two years of diagnosis, according to a study in... View Article
Hepatitis C virus (HCV) infection is known to cause hepatocellular carcinoma (HCC) and subtypes of non-Hodgkin lymphoma (NHL).
Recent research has focused on some etiological factors to help predict who is at risk for developing cutaneous T-cell lymphoma (CTCL), which occurs disproportionately in veterans.
Presumptively caused by Agent Orange exposure, cutaneous T-cell lymphoma occurs disproportionately among male veterans. Complicating the clinical approach, the disorders comprising CTCL are similar but differ greatly in response to therapy. New genomic research on the rare cancer, however, is holding out promise for better, more-customized treatment.
ROCKVILLE, MD — While previous studies have reported that survivors of non-Hodgkin lymphoma (NHL) have an increased risk of developing cutaneous melanoma, risks associated with specific treatments and immune-related risk factors have not been quantified.To... View Article
SAN ANTONIO — New research directly links disrupted metabolism to a common and often fatal type of lymphoma, according to an article in Nature Communications.1“The link between metabolism and cancer has been proposed or inferred... View Article
As the healthcare system with the most experience treating older men, the VA has special expertise in treating uncommon diseases that plague them, such as peripheral T-cell lymphoma. The current challenge for clinicians is to... View Article
An estimated 5-10% of all cutaneous T-cell lymphoma (CTCL) diagnosed each year occurs in veterans treated by the VA. The cancer, classified as presumptively caused by Agent Orange exposure, is notoriously difficult to diagnose and... View Article
A long sought-after bill that would make it easier for Blue Water Navy veterans to receive Agent Orange benefits has been passed by a key House of Representatives committee.
CTCL 6-10 Times More Common in Veterans; Agent Orange a Factor New Therapies Raise Optimism about Treatment
Chances are, if you haven’t trained or practiced at the VA, you haven’t seen cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin lymphoma.
BOSTON — With an aging population, cognitive impairment is increasingly common. The question raised by a new study was what effect that has on survival for older patients with hematologic cancers.
LEBANON, NH — Extracorporeal photopheresis (ECP) is a leukapheresis-based therapeutic procedure that has been approved by the Food and Drug Administration (FDA) for the treatment of advanced cutaneous T-cell lymphoma (CTCL) since 1988. In ECP,... View Article
STANFORD, CA — Patients with cutaneous T-cell lymphoma (CTCL) might have a promising new treatment option, according to a study presented at a recent conference. In a presentation at the 2017 American Society of Hematology... View Article
MINNEAPOLIS—Exposure to Agent Orange was not associated with either poor prognostic factors or shortened overall survival in a large veteran population with chronic lymphocytic leukemia (CLL), even though it is associated with development of the... View Article
VA Secretary David Shulkin, MD, said he has made a decision on the expansion of the list of presumptive conditions for Agent Orange compensation and has passed it on to the next step in the process.